

Date 26th May 2010

Dr Carole Longson
Director
Health Technology Evaluation Centre
National Institute for Health and Clinical Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 6NA



Quarry House
Quarry Hill
Leeds
LS2 7UE

Tel: [REDACTED]

Dear Carole

Patient Access Scheme – Tarceva (erlotinib) in the maintenance treatment of advanced or metastatic non-small cell lung cancer.

I am writing to confirm the Department of Health's position on the Patient Access Scheme (PAS) arrangements that have been proposed by Roche for Tarceva (erlotinib) in the maintenance treatment of advanced or metastatic non-small cell lung cancer.

The Department is content for NICE to consider the PAS proposed by Roche.

Yours sincerely

[REDACTED]